Paper 38 - DEFINING NOVEL BENCHMARK VALUES FOR OUTCOMES OF COMPREHENSIVE RESECTION OF PRIMARY RETROPERITONEAL LIPOSARCOMA

Author(s)

• 

  Fabio Tirotta, MD

  Consultant Surgeon - Sarcoma Surgical Oncologist
  University Hospitals Birmingham NHS Foundation Trust
  Birmingham, England, United Kingdom

  Slides

Co-Author(s)

• 

  Marco Fiore, MD, FACS, FEBS

  Surgeon
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milano, Lombardia, Italy
• SB

  Sylvie Bonvalot, MD

  Institut Curie
  Paris, Ile-de-France, France
• DS

  Dirk Strauss, MD

  The Royal Marsden Hospital
  London, England, United Kingdom
• PR

  Piotr Rutkowski, MD PhD

  Maria Sklodowska-Curie National Research Institute of Oncology
  Warsaw, Mazowieckie, Poland
• 

  David E. Gyorki, MBBS MD FRACS

  Surgical Oncologist
  Peter MacCallum Cancer Centre
  Melbourne, Australia, Victoria, Australia
• Wv

  Winan van Houdt, MD, PhD

  Surgical Oncologist
  Netherlands Cancer Institute
  Amsterdam, Noord-Holland, Netherlands
• 

  Dario Callegaro, MD

  Attending Surgical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• 

  Markus Albertsmeier, MD

  Attending Surgeon
  LMU Hospital, Ludwigs-Maximilians-Universität Munich
  Munich, Bayern, Germany
• DT

  Dimitrios Tzanis, MD, PhD

  Institut Curie
  Paris, Ile-de-France, France
• FC

  Ferdinando CM Cananzi, MD

  IRCCS Humanitas Research Hospital
  Rozzano, Milan, Lombardia, Italy
• JS

  Jason K. Sicklick, M.D., FACS

  Professor/Principal Investigator
  University of California, San Diego
  La Jolla, California, United States
• 

  John Mullinax, MD

  Associate Member
  Moffitt Cancer Center
  Tampa, Florida, United States
• MW

  Michelle Jennifer Wilkinson, FRCS, PhD

  Ms
  The Royal Marsden Hospital
  London, England, United Kingdom
• 

  Valerie Grignol, MD (she/her/hers)

  Associate Professor of Surgery
  The Ohio State University James Cancer Hospital
  Columbus, Ohio, United States
• KC

  Kenneth Cardona, MD

  Winship Cancer Institute
  Atlanta, Georgia, United States
• TB

  Toufik Bouhadiba, MD

  Institut Curie
  Paris, Ile-de-France, France
• MN

  Marko Novak, MD

  Institute of Oncology Ljubljana
  Ljubljana, Ljubljana, Slovenia
• SV

  Sergio Valeri, MD

  Università Campus Bio-Medico
  Rome, Lazio, Italy
• 

  Mark Fairweather, MD

  Surgical Oncologist
  Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States
• 

  Samuel Ford, PhD, FRCS

  Consultant Sarcoma Surgeon
  Queen Elizabeth Hospital
  Birmingham, England, United Kingdom
• JS

  Jacek Skoczylas, MD

  Maria Sklodowska-Curie National Research Institute of Oncology
  Warsaw, Mazowieckie, Poland
• HS

  Hayden Snow, MD

  Surgeon
  Peter MacCallum Cancer Centre
  Melbourne, Victoria, Australia
• AH

  Andrew J. Hayes, MD PhD

  Prof
  Royal Mardsen Hospital
  London, England, United Kingdom
• JH

  James Hodson, BSc

  University Hospitals Birmingham NHS Foundation Trust
  Birmingham, England, United Kingdom
• CR

  Chandrajit P. Raut, MD, MSc

  Chief, Division of Surgical Oncology (BWH) and Chair, Department of Surgery (DFCI)
  Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School
  Boston, Massachusetts, United States
• 

  Alessandro Gronchi, MD, FSSO (he/him/his)

  Chief of Sarcoma Service and Chair of the Department of Surgery
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy